Glaukos Corporation
RHO KINASE INHIBITOR RELEASING IMPLANTS AND RELATED METHODS OF USE
Last updated:
Abstract:
The present disclosure is directed to intracameral implants for treating and/or preventing corneal disorders, diseases, and/or conditions, such as corneal endothelial dystrophies. The intracameral implants can be configured to provide a sustained release of a therapeutic agent, such as a Rho kinase inhibitor, for a prolonged period of time. The intracameral implants can include a non-bioresorbable anchor or a bioresorbable matrix.
Status:
Application
Type:
Utility
Filling date:
2 Jun 2021
Issue date:
9 Dec 2021